Sema4, a patient-centered health intelligence company, today announced additional nationwide support for organizations seeking a COVID-19 testing solution that enables rapid, informed decisions. Sema4 now has the capacity to process up to 15,000 COVID-19 viral tests per day in its certified, state-of-the-art lab in Connecticut, while still providing reliable and accurate results within approximately 24-48 hours of receiving the sample for the test. Sema4’s end-to-end solution for governmental organizations and other entities also includes antibody testing, and a seamless digital experience for those who order and receive the tests.
Sema4’s wide breadth of offerings is available to governmental organizations that want to keep their local and regional communities safe by testing their residents and employees. Sema4 already has a formal partnership with the State of Connecticut, which is using the company as a COVID-19 testing provider for Connecticut residents. Sema4 can also support higher education institutions seeking to reopen their campuses and protect the health of students, faculty, and staff. Additionally, the company’s COVID-19 testing solution is available to large businesses that want to safely reopen and stay open, and healthcare providers seeking to test patients prior to a procedure or appointment.
In addition to being able to process up to 15,000 COVID-19 viral tests per day in its Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited laboratory, Sema4 can also process 5,000 antibody tests per day. Results are rapidly returned within around 48 hours for the antibody test. For viral tests, Sema4 accepts nasopharyngeal swabs and oropharyngeal swabs, which are collected by a healthcare provider or at an authorized collection site.
Sema4’s testing solution also includes a significant digital component: a web portal and Sema4 Works, a custom app. Enterprises that work with Sema4 use the web portal to register employees or other people they want to get tested for COVID-19, order testing kits, and track the status of samples and results. Those individuals can utilize both the web portal and Sema4 Works to provide consent and register for testing and receive test results.
“As many states across the country navigate significant spikes in COVID infections, we are pleased to further increase viral testing capacity in our world-class laboratory to support them,” said Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4. “Our ability to rapidly process these tests and provide accurate results is critical to governmental organizations and other entities seeking to mitigate the impact of COVID-19. As a health intelligence company, they can also benefit from Sema4’s full end-to-end digital testing solution that is underpinned by our technology expertise and our industry-leading science experience.”
The COVID-19 viral tests used by Sema4 are manufactured by PerkinElmer, and the antibody tests are run on the Abbott Alinity™ system. Both tests achieve the highest levels of sensitivity and specificity that have been demonstrated for these types of COVID-19 tests. Tested individuals can share their anonymized data with the scientific community to support COVID-19-related research.
Governmental organizations, higher education institutions, large businesses, and healthcare providers interested in learning more about Sema4’s back-to-work program can visit this URL to get more information: sema4.com/covid19-testing.
About Sema4
Sema4 is a patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005375/en/